Artivion (NYSE:AORT) Earns “Buy” Rating from Needham & Company LLC

Artivion (NYSE:AORT)‘s stock had its “buy” rating reaffirmed by research analysts at Needham & Company LLC in a research report issued on Monday, Marketbeat Ratings reports. They currently have a $44.00 price target on the stock. Needham & Company LLC’s target price indicates a potential upside of 76.25% from the company’s current price.

AORT has been the subject of several other research reports. Stifel Nicolaus set a $45.00 price target on shares of Artivion in a research note on Monday, June 1st. Canaccord Genuity Group reissued a “buy” rating and issued a $36.00 price objective on shares of Artivion in a research note on Tuesday, June 16th. Weiss Ratings downgraded Artivion from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, June 8th. LADENBURG THALM/SH SH raised Artivion from a “neutral” rating to a “buy” rating and set a $42.00 target price for the company in a research report on Friday, April 10th. Finally, Citizens Jmp lowered their target price on Artivion from $53.00 to $48.00 and set a “market outperform” rating for the company in a report on Friday, May 8th. Seven investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $44.17.

Artivion Price Performance

Artivion stock opened at $24.96 on Monday. The stock has a market cap of $1.21 billion, a price-to-earnings ratio of 104.02 and a beta of 1.26. The company has a debt-to-equity ratio of 0.48, a current ratio of 3.86 and a quick ratio of 2.80. Artivion has a 1 year low of $19.16 and a 1 year high of $48.25. The firm has a 50-day moving average of $22.53 and a two-hundred day moving average of $32.65.

Insiders Place Their Bets

In other Artivion news, SVP Andrew M. Green sold 44,001 shares of the company’s stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $20.70, for a total transaction of $910,820.70. Following the completion of the sale, the senior vice president owned 60,259 shares in the company, valued at $1,247,361.30. This represents a 42.20% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.30% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Artivion

A number of hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. raised its holdings in Artivion by 4.7% in the fourth quarter. Vanguard Group Inc. now owns 3,170,089 shares of the company’s stock worth $144,588,000 after purchasing an additional 141,030 shares in the last quarter. Morgan Stanley grew its position in shares of Artivion by 0.8% in the 4th quarter. Morgan Stanley now owns 2,256,742 shares of the company’s stock worth $102,930,000 after buying an additional 18,248 shares during the last quarter. State Street Corp grew its position in shares of Artivion by 2.9% in the 4th quarter. State Street Corp now owns 1,584,920 shares of the company’s stock worth $72,288,000 after buying an additional 44,641 shares during the last quarter. Fred Alger Management LLC raised its stake in shares of Artivion by 4.2% during the 4th quarter. Fred Alger Management LLC now owns 1,372,572 shares of the company’s stock worth $62,603,000 after acquiring an additional 55,322 shares in the last quarter. Finally, Conestoga Capital Advisors LLC bought a new position in shares of Artivion during the 1st quarter worth approximately $43,044,000. 86.37% of the stock is currently owned by hedge funds and other institutional investors.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.